What is Wellinks?
Wellinks is dedicated to transforming the lives of individuals suffering from COPD, the third leading cause of death by disease in the U.S. and a significant chronic condition. The company offers a personalized, virtual-first COPD management system designed to break down traditional healthcare barriers. Through its comprehensive platform, Wellinks delivers virtual pulmonary rehabilitation, health coaching, and remote monitoring via connected devices and a user-friendly smartphone application. This innovative approach ensures patients receive necessary, evidence-based care outside of conventional clinical settings, all managed by a seasoned team of digital health veterans.
How much funding has Wellinks raised?
Wellinks has raised a total of $44.8M across 3 funding rounds:
Private Equity
$795K
Series B
$19M
Series C
$25M
Private Equity (2016): $795K, investors not publicly disclosed
Series B (2019): $19M led by HighCape Capital
Series C (2021): $25M supported by The Morningside Group, Connecticut Innovations, Stonehenge Capital, Benslie, and HighCape Capital
Key Investors in Wellinks
The Morningside Group
Morningside Group is a private equity and venture capital firm founded in 1986, known for its entrepreneurial investment professionals with deep industry knowledge and a commitment to social responsibility.
HighCape Capital
HighCape Capital is a growth equity fund established in 2013, specializing in assisting innovative Life Sciences companies with a focus on Connected Health, Medical Devices, and Biotechnology.
Connecticut Innovations
Connecticut Innovations is Connecticuts strategic venture capital arm, providing financing and strategic guidance to innovative companies, with dedicated funds for sectors including AI/quantum, climate tech, and biosciences.
What's next for Wellinks?
The recent major strategic investment signifies a pivotal moment for Wellinks, positioning it for accelerated scaling and market penetration. With enterprise-level backing, the company is poised to expand its reach, enhance its technological infrastructure, and further develop its virtual care offerings. This capital will likely fuel advancements in patient engagement, data analytics for personalized treatment plans, and broader integration into the healthcare ecosystem. The strategic nature of this financing suggests a focus on solidifying its market leadership and potentially exploring new therapeutic areas or partnerships within the chronic disease management space.
See full Wellinks company page
